Clinical Trial Detail

NCT ID NCT04317105
Title Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Copanlisib + Ipilimumab + Nivolumab

Copanlisib + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST